Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049513 | 0.86 | HSD17B10 (0.32) | HSD17B10TDP1 | |
| SCHEMBL11023381 | 0.86 | HTT (0.41) | CYP3A4 | |
| SCHEMBL7129182 | 0.83 | HTT (0.34) | HSD17B10TDP1 | |
| SCHEMBL3940811 | 0.83 | HTT (0.34) | HSD17B10TDP1 | |
| SCHEMBL28738510 | 0.79 | MEN1 (0.46) | — | |
| SCHEMBL27535378 | 0.79 | MEN1 (0.46) | — | |
| SCHEMBL27438323 | 0.79 | MEN1 (0.46) | — | |
| SCHEMBL3492554 | 0.78 | DNM1 (0.42) | CYP3A4TDP1 | |
| SCHEMBL7577706 | 0.78 | TLR2 (0.41) | CYP3A4 | |
| SCHEMBL12818983 | 0.77 | CYP3A4 (0.46) | CYP3A4HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147017-A1 | INDIUM MIXED-PNICTOGENIDE QUANTUM DOTS | QUANTUM SCIENCE LTD (GB) | 2024-07-11 | — | — | WO | claimed |
| WO-2024147016-A1 | METHOD FOR PRODUCING LEAD-FREE NANOCRYSTALS | QUANTUM SCIENCE LTD (GB) | 2024-07-11 | — | — | WO | claimed |
| EP-3484908-A1 | NON-NUCLEOSIDIC SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | AM Chemicals Llc (US) | 2019-05-22 | — | — | EP | claimed |
| US-10189946-B2 | Process for preparing polyamines | BASF SE (DE) | 2019-01-29 | — | — | US | claimed |
| EP-3313896-A1 | ALDIMINES AND KETIMINES AS INITIATORS IN HARDENER SYSTEMS AND CORRESPONDING RESIN COMPOSITIONS FOR USES INCLUDING FIXING TECHNOLOGY | fischerwerke GmbH & Co. KG (DE) | 2018-05-02 | — | — | EP | claimed |
| WO-2018013999-A1 | NON-NUCLEOSIDIC SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | AM CHEMICALS LLC (US) | 2018-01-18 | — | — | WO | claimed |
| WO-2017067621-A1 | ALDEHYDES AND KETONES AS INITIATORS IN HARDENER SYSTEMS AND CORRESPONDING RESIN COMPOSITIONS FOR USE, INTER ALIA, IN FASTENING TECHNOLOGY | FISCHERWERKE GMBH & CO. KG (DE) | 2017-04-27 | — | — | WO | claimed |
| US-9631070-B2 | Filler materials having surface coating made from water soluble polyamides | EMS-PATENT AG (CH) | 2017-04-25 | — | — | US | claimed |
| US-20170066882-A1 | PROCESS FOR PREPARING POLYAMINES | BASF SE (DE) | 2017-03-09 | — | — | US | claimed |
| WO-2016206777-A1 | ALDIMINES AND KETIMINES AS INITIATORS IN HARDENER SYSTEMS AND CORRESPONDING RESIN COMPOSITIONS FOR USES INCLUDING FIXING TECHNOLOGY | FISCHERWERKE GMBH & CO. KG (DE) | 2016-12-29 | — | — | WO | claimed |
| WO-2007031534-A1 | METHOD FOR THE PRODUCTION OF BETA-AMINOPROPIONIC ACID DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-22 | — | — | WO | claimed |
| US-20070066561-A1 | Drug delivery and targeting with vitamin B12 conjugates | NEW YORK UNIVERSITY (US) | 2007-03-22 | — | — | US | claimed |
| US-6890765-B2 | Particles for immunoassays and methods for treating the same | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2005-05-10 | — | — | US | claimed |
| US-6777246-B2 | REDUCES INTERFERENCE IN PARTICLE AGGLUTINATION ASSAYS BY SUPPRESSING NON-SPECIFIC INTERACTIONS | ROCHE DIAGNOSTICS GMBH (DE) | 2004-08-17 | — | — | US | claimed |
| US-20030138974-A1 | Tertiary amine compounds for use in immunoassays | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2003-07-24 | — | — | US | claimed |
| EP-1321770-A2 | Tertiary amine compounds for use in immunoassays | Roche Diagnostics GmbH (DE) | 2003-06-25 | — | — | EP | claimed |
| EP-1319953-A1 | Particles for immunoassays and methods for treating the same | BOEHRINGER MANNHEIM GMBH (DE) | 2003-06-18 | — | — | EP | claimed |
| US-20030092201-A1 | Particles for immunoassays and methods for treating the same | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2003-05-15 | — | — | US | claimed |
| US-20030087458-A1 | Particles for immunoassays and methods for treating the same | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2003-05-08 | — | — | US | claimed |
| US-5429672-A | Silica effect control during metal deposition | HILEMN LABORATORIES, INC. (US) | 1995-07-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066561-A1 | Drug delivery and targeting with vitamin B12 conjugates | SLC19A1, FOLR2, FOLR1 | CYP3A4 1625/4885HSD17B10 1838/4885TDP1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.